Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05347485 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
A Phase 2 study, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT05347485 is a Phase 2 study that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 86 participants.
The verdict
NCT05347485, a Phase 2 study, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
Interventions
- DRUG Cilta-cel
- DRUG Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-05-13 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05347485
The ClinicalTrials.gov registry entry for NCT05347485 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cilta-cel is the first listed.
NCT05347485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05347485 about?
NCT05347485 is a clinical study titled "A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma". The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
What is the current status of trial NCT05347485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2022-05-13. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT05347485?
The interventions under investigation include: Cilta-cel (DRUG), Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) (DRUG).
Who is sponsoring clinical trial NCT05347485?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.